ALLO
Income statement / Annual
Last year (2023), Allogene Therapeutics, Inc.'s total revenue was $95,000.00,
a decrease of 60.91% from the previous year.
In 2023, Allogene Therapeutics, Inc.'s net income was -$327.27 M.
See Allogene Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
| Operating Revenue |
$95,000.00
|
$243,000.00
|
$38.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$242.91 M |
$16.73 M |
$13.07 M |
$11.54 M |
$5.03 M |
$1.50 M |
$0.00 |
| Gross Profit |
-$242.82 M |
-$16.49 M |
$25.42 M |
-$11.54 M |
-$5.03 M |
-$1.50 M |
$0.00 |
| Gross Profit Ratio |
-2555.99 |
-67.84 |
0.66 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$242.91 M
|
$256.39 M
|
$220.18 M
|
$192.99 M
|
$144.54 M
|
$151.86 M
|
$0.00
|
| General & Administrative
Expenses |
$71.67 M
|
$79.31 M
|
$74.11 M
|
$65.26 M
|
$57.47 M
|
$40.98 M
|
$24,000.00
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$22,000.00
|
| Selling, General &
Administrative Expenses |
$71.67 M
|
$79.31 M
|
$74.11 M
|
$65.26 M
|
$57.47 M
|
$40.98 M
|
$2,000.00
|
| Other Expenses |
$13.25 M |
-$1.75 M |
-$2.93 M |
-$1.14 M |
-$268,000.00 |
-$21.21 M |
$0.00 |
| Operating Expenses |
$327.83 M |
$335.69 M |
$294.28 M |
$258.24 M |
$202.01 M |
$192.84 M |
$2,000.00 |
| Cost And Expenses |
$327.83 M |
$335.69 M |
$294.28 M |
$258.24 M |
$202.01 M |
$192.84 M |
$2,000.00 |
| Interest Income |
$18.31 M |
$4.57 M |
$1.71 M |
$9.16 M |
$17.35 M |
$5.79 M |
$0.00 |
| Interest Expense |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$3.36 M |
$0.00 |
| Depreciation &
Amortization |
$14.20 M
|
$14.30 M
|
$10.45 M
|
$11.54 M
|
$5.03 M
|
$1.50 M
|
$24,000.00
|
| EBITDA |
-$300.29 M
|
-$321.24 M
|
-$169.74 M
|
-$250.81 M
|
-$179.90 M
|
-$206.76 M
|
$22,000.00
|
| EBITDA Ratio |
-3160.98 |
-1380.45 |
-6.65 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
-3449.86
|
-1380.45
|
-6.65
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
$472,000.00
|
-$4.88 M
|
-$1.86 M
|
$8.02 M
|
$17.08 M
|
-$18.78 M
|
-$22,000.00
|
| Income Before Tax |
-$327.27 M |
-$332.63 M |
-$257.01 M |
-$250.22 M |
-$184.93 M |
-$211.62 M |
-$2,000.00 |
| Income Before Tax Ratio
|
-3444.89
|
-1368.86
|
-6.68
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
-$2.82 M |
-$12.17 M |
-$16.75 M |
-$331,000.00 |
-$117,000.00 |
-$24,000.00 |
| Net Income |
-$327.27 M |
-$329.82 M |
-$244.84 M |
-$233.47 M |
-$184.59 M |
-$211.51 M |
-$2,000.00 |
| Net Income Ratio |
-3444.89 |
-1357.26 |
-6.36 |
0 |
0 |
0 |
0 |
| EPS |
-2.09 |
-2.3 |
-1.8 |
-1.94 |
-1.83 |
-7.31 |
0 |
| EPS Diluted |
-2.09 |
-2.3 |
-1.8 |
-1.94 |
-1.83 |
-7.31 |
0 |
| Weighted Average Shares
Out |
$156.93 M
|
$143.15 M
|
$135.82 M
|
$120.37 M
|
$101.06 M
|
$28.95 M
|
$117.93 M
|
| Weighted Average Shares
Out Diluted |
$156.93 M
|
$143.15 M
|
$135.82 M
|
$120.37 M
|
$101.06 M
|
$28.95 M
|
$117.93 M
|
| Link |
|
|
|
|
|
|
|
